Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipratropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.63 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 3/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipratropium SCHEMBL4231044 | 1.00 | CHRM2 (0.63) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL28250222 | 0.99 | CHRM2 (0.65) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL28223580 | 0.99 | CHRM2 (0.64) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL2169666 | 0.99 | CHRM2 (0.64) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL28250221 | 0.98 | CHRM2 (0.63) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL27974717 | 0.97 | CHRM2 (0.60) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL2167530 | 0.97 | CHRM2 (0.60) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL29400593 | 0.97 | CHRM2 (0.60) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL117888 | 0.96 | CHRM2 (0.60) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL691922 | 0.84 | CHRM2 (0.64) | CHRM2CHRM5CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11904088-B2 | Methods for measuring dose content uniformity performance of inhaler and nasal devices | PROVERIS SCIENTIFIC CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| CN-111511429-B | Control unit for use with a breathing assistance device | 皇家飞利浦有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230321370-A1 | SYSTEMS AND METHODS FOR INHALER TESTING | PROVERIS SCIENTIFIC CORPORATION | 2023-10-12 | — | — | US | disclosed |
| EP-4228725-A1 | SYSTEMS AND METHODS FOR INHALER TESTING | Proveris Scientific Corporation (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230181846-A1 | METHODS FOR MEASURING DOSE CONTENT UNIFORMITY PERFORMANCE OF INHALER AND NASAL DEVICES | PROVERIS SCIENTIFIC CORPORATION | 2023-06-15 | — | — | US | disclosed |
| CN-115148353-A | Clinical decision support system for estimating drug-related therapy optimization | 西门子医疗有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-114423454-A | Administration of anti-tryptase antibodies | 豪夫迈·罗氏有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022081847-A1 | SYSTEMS AND METHODS FOR INHALER TESTING | PROVERIS SCIENTIFIC CORPORATION (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20210113797-A1 | CONTROL UNIT FOR USE WITH A RESPIRATORY ASSIST DEVICE | KONINKLIJKE PHILIPS N.V. (NL) | 2021-04-22 | — | — | US | disclosed |
| EP-1855711-B1 | USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS | BIOGEN IDEC INC (US) | 2009-06-17 | — | — | EP | disclosed |
| CN-101422436-A | Dry powder composite for suction | JIANGSU CHIA TAI TIANQING PHAR (CN) | 2009-05-06 | — | — | CN | disclosed |
| US-20080254030-A1 | Using B cell survival factor (BAFF) agonist as therapeutic in treatment of asthma | BIOGEN IDEC MA INC. | 2008-10-16 | — | — | US | disclosed |
| EP-1865985-A2 | KIM-1 ANTIBODIES FOR TREATMENT OF TH2-MEDIATED CONDITIONS | Biogen Idec MA Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1855711-A2 | USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS | Biogen Idec MA Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006094134-A2 | KIM-1 ANTIBODIES FOR TREATMENT OF TH2-MEDIATED CONDITIONS | BIOGEN IDEC MA INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006081516-A2 | USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS | BIOGEN IDEC MA INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20050136033-A9 | Method of treating allergen induced airway disease | MACK MATTHIAS (DE) | 2005-06-23 | — | — | US | disclosed |
| US-20040132657-A1 | Method of treating allergen induced airway disease | MICROMET AG (DE) | 2004-07-08 | — | — | US | disclosed |
| US-20040033209-A1 | Method of treating allergen induced airway disease | MICROMET AG (DE) | 2004-02-19 | — | — | US | disclosed |